Evaluation by polymerase chain reaction of cytomegalovirus reactivation in intensive care patients under mechanical ventilation

Abstract

Objective: The study was undertaken to determine if critically ill patients under mechanical ventilation could reactivate latent cytomegalovirus (CMV) in either lung or blood.

Design: Prospective study in critically ill patients.

Setting: The study was performed in a multidisciplinary intensive care unit in a university hospital.

Patients: 23 non-immunocompromised, mechanically ventilated patients who were anti-CMV immunoglobulin G-positive. Ten immunocompromised patients with active CMV infection and 16 asymptomatic CMV seropositive non-immunocompromised patients constituted the positive and negative control groups.

Measurements and results: The presence of CMV in blood and bronchoalveolar lavage (BAL) was evaluated by both viral cultures and polymerase chain reaction (PCR). Thirty-seven blood and 22 BAL samples were investigated. Sequential samples were evaluated in 8 patients. For PCR, a 290 bp fragment in the first exon of the immediate early 1 gene was amplified. In order to exclude inhibitors of PCR amplification, a 268 bp fragment of the β-globin gene was concurrently amplified in all samples. Viral cultures of blood and BAL were negative in all 23 non-immunocompromised, mechanically ventilated patients. Moreover, no CMV DNA could be amplified in blood or BAL samples, whereas a β-globin amplification was observed in all samples.

Conclusion: In a series of 23 critically ill patients under mechanical ventilation who were seropositive for CMV, no reactivation of CMV in blood or lung was demonstrated.

Key words Cytomegalovirus · Polymerase chain reaction · Reactivation · Critically ill patients

Introduction

Cytomegalovirus (CMV) infection – especially CMV pneumonia – is a major cause of illness and death in immunocompromised patients [1]. Infection with CMV is usually asymptomatic in the immunocompetent host [2], but there are a few reports of infection or reactivation of CMV with viral detection in blood in patients sepsis [3, 4]. The incidence of such events in blood has been reported to range between 20 and 96% in patients with sepsis. After primary infection, the virus persists in the host as a latent infection, which can periodically reactivate to cause active infection [2]. The mechanism of reactivation is unknown but enhanced tumor necrosis factor levels may reactivate CMV [4]. White blood cells, especially monocytes, may harbor the latent virus in healthy seropositive individuals [5, 6], and CMV is known to be transmitted by blood transfusion [7]. It has also been shown that the lung could be a site of CMV latency in humans [8]. The control of CMV replication by the host involves mechanisms of both natural and acquired immunity [9, 10]. The natural
killer cells are the principal effector cells regarding natural immunity, and B-cells and T-cells (especially CD8 T-cells) are the main components of the acquired immunity. These cell types are interconnected through accessory cells [9, 10]. Critically ill patients frequently demonstrate profound immunologic abnormalities as a result of either their illness or its treatment [11]. The present study was therefore designed to investigate the hypothesis that critically ill, mechanically ventilated, non-immunocompromised patients could reactivate latent CMV either in blood or lung.

We used an in vitro gene amplification technique, the polymerase chain reaction, which has been applied to the detection of CMV DNA in peripheral blood leukocytes (PBLs) [12–16] and bronchoalveolar lavage (BAL) specimens [17–19]. PCR amplification of a 290-bp fragment of the exon 1 of the major immediate early gene was used to test the DNA extracted from blood or BAL cells collected in critically ill, mechanically ventilated, non-immunocompromised patients [20]. Conventional viral culture and rapid culture by the shell vial technique were performed simultaneously [21]. The results obtained failed to demonstrate CMV reactivation in blood or lung from this series of 23 patients.

Patients and methods

Patients

Between January and August 1993, 23 non-immunocompromised patients admitted to the intensive care unit were included in this study. We have evaluated anti-CMV immunoglobulin G (IgG)-positive patients who had: (a) an expected duration of hospitalisation for at least 5 days; (b) a need for mechanical ventilation; (c) a previous surgical procedure, or a sepsis syndrome, or a pulmonary injury. Upon entry into the study, the hospital records of each patient were reviewed, and the following clinical variables were noted: age, sex, severity of underlying medical conditions stratified according to the criteria of McCabe and Jackson as fatal, ultimately fatal, and non-fatal [22], first-day Acute Physiology and Chronic Health Evaluation II score, which is an index of the severity of illness of patients admitted to an ICU [23], white blood cell count, serum creatinine, bilirubin and aspartate aminotransferase, partial pressure of oxygen fractional inspired oxygen (PFO2) ratio, pulmonary impairment determined by the Lung Injury Score described by Murray et al. [24], duration of admission, and final clinical outcome. The criteria of the sepsis syndrome have been previously reported [25] and include: (1) clinical suspicion of infection; (2) temperature <35.5±C or >38.3±C; (3) tachycardia >90 beats min; (4) mechanical ventilation; (5) inadequate organ perfusion or dysfunction as expressed by one of the following: alteration in mental status, hypoxemia (partial pressure of oxygen in arterial blood <72 mmHg at FIO2=0.21), elevated plasma lactate or oliguria (urine output <30 ml or 0.5 ml/kg for at least 1 h). Septic shock was defined with the above criteria plus: a decrease in systolic arterial pressure (<90 mmHg) despite adequate vascular filling; and need for vasoactive drugs (dopamine >5 µg/kg per min, dobutamine, epinephrine, or norepinephrine).

Twelve patients received packed red blood cells during the month prior to inclusion in the study. In order to exclude exogenous transmission of CMV, packed red cells were filtered through a SQ40 Pall filter (PALL Biomédical France, Saint-Germain-en-Laye, France). According to the manufacturer, such a filter removes ≥95% of the leukocytes in a unit of normal blood.

Ten additional patients with kidney (n=5) or bone marrow (n=5) transplantation and active CMV infection were also studied. Blood and BAL cultures were positive for CMV. These patients constituted the positive control group.

Sixteen asymptomatic non-immunocompromised patients who were CMV-seropositive constituted the negative control group. In all of these patients, the search for CMV by viral cultures in BAL fluid, blood or urine was negative.

Serology

The presence of specific IgG anti-CMV antibodies was tested in serum using an enzyme-linked immunosorbent assay (CMV IgG Wellcome (Dartford, Kent, UK)).

Specimen collection

BAL procedure

Among the 23 patients studied, 14 patients underwent a BAL procedure. BAL (n=22) was performed at a mean of 10 days (range, 1–41 days) after ICU admission for diagnosis of new or persistent lung infiltrates ultimately related to pneumonia (n=17), pulmonary edema (n=3), and atelectasis (n=3) (Fig. 1). Therefore, in 4 patients, BAL samples were evaluated on ≥2 occasions. Briefly, after wedging the bronchoscope into a subsegmental bronchus of either the right middle lobe or the lobe with maximal infiltration on chest roentgenograms, sterile 0.9% sodium chloride was infused in 20- or 50-ml aliquots, for a total of 150 to 200 ml, and gently aspirated after each instillation. Total cell counts were evaluated using a hemocytometer, and differential counts were performed on cytocentrifuge preparation using a CytoSpin 2 centrifuge (Shandon Southern Products, Cheshire, UK), stained with Wright-Giemsa stain. Cytocentrifuge preparations of these cell populations showed a mean (±SEM) of 16.6±4% alveolar macrophages, 80±4.5% neutrophils, 3.3±0.9 lymphocytes, and 0% eosinophils. The mean (±SEM) total cell count was 535.8±127.4 cells ±10³/ml.

Peripheral blood leukocytes

Blood samples (n=37) were collected from all the 23 patients at a mean of 5 days (range 1–41 days) for the first sample and at a mean of 17 days (range 6–29 days) for the others (Fig. 1). Finally, in 8 patients sequential samples were taken.

![Fig. 1 Distribution of blood and BAL samples after ICU admission](image-url)
Viral isolation

Both conventional viral culture (up to 21 days) and rapid culture by the shell vial technique were used for BAL fluid and blood, as previously described [21].

BAL and blood sample preparation

PBLs were isolated from 5 ml of ethylenediaminetetraacetic acid (EDTA) blood. The buffy coat was aspirated and treated with lysis buffer (0.9 mM ammonium bicarbonate, 0.13 M ammonium-15N chloride) to lyse red cells. The cell pellet (10^6 cells) was stored at -20°C.

BAL samples were centrifuged at 1000 rpm for 10 min at 4°C. The supernatant was removed and the cell pellet was resuspended in the lysis buffer at a concentration of 10^6 cells/ml. Aliquots of 10^6 cells were stored at -20°C until the sample was processed for testing.

DNA extraction

DNA was extracted by a rapid extraction method [26]. Briefly, the cells were resuspended in 50 μl of solution A (100 mM KCl, 10 mM Tris-HCl (pH 8.3), 2.5 mM MgCl2), and in 50 μl of solution B (10 mM Tris-HCl (pH 8.3), 2.5 mM MgCl2, 1% Nonidet-P40, 1% Tween 20). The cells were digested by incubation with proteinase K (200 μg/ml) at 60°C for 1 h. Proteinase K was then inactivated by placing the tube in a 95°C water bath for 10 min. The DNA released with this procedure can be amplified directly.

Control human CMV (HCMV) viral DNA

The usual fibroblast (MRC5) cell line was infected in vitro with a wild-type strain of HCMV isolated from a patient with acute CMV infection. The presence of CMV was confirmed by the observation of the characteristic cytopathic effect. The cells were scraped and harvested 5 to 7 days after being infected and the DNA was extracted as described above.

Conditions for polymerase chain reaction (PCR) amplification

PCR was performed according to the method described previously [19]. For PCR amplification, we chose to amplify a 290-bp segment located in the exon 1 of the HCMV immediate early gene [20]. This region of the genome was selected since it is markedly conserved between the various human CMV strains [27]. Two primers were used: 5'-ATCGCCTGGAGACGCCATCC-3'; 3' primer sequence, 5'-ATCGCCTGGAGACGCCATCC-3'; 3' primer sequence, 5'-CTGCAGAGACGCCATCC-3'. These oligomers were designed by Genentech and were synthesized on a DNA synthesizer as recommended by the manufacturer (Genentech, Paris, France). Amplification reactions were performed according to the method described previously [28]. Ten μl of DNA samples were routinely amplified for 30 cycles (DNA Thermal Cycler, Perkin-Elmer-Cetus) using 2.5 U/100 μl of Taq DNA polymerase (Perkin-Elmer-Cetus) in 1.5 mM MgCl2 with reaction times of 1 min at 55°C for annealing, 2 min at 72°C for extension, and 1 min at 94°C for denaturation.

We controlled for internal consistency standards, i.e., DNA from HCMV-infected MRC5 fibroblast cells was included in each PCR reaction. Negative controls contained the above PCR mixture, with distilled water replacing the template DNA to control for PCR product contamination of reagents. To minimize the risk of contamination, the PCR technique was physically separated from the laboratory area in which DNA extraction was performed. To exclude the presence of polymerase inhibitors and to control the quality of the DNA extracted, a 268-bp fragment of the human β-globin gene (GenAmplimer Betaglobin primers; Perkin-Elmer-Cetus) was amplified in parallel.

Analysis of PCR amplification products

Amplified sequences were analyzed by direct gel electrophoresis and by slot-blot hybridization assay using an oligonucleotide probe (5'-CATTGGAACGCGGATTC-3', purchased from Genentech). For direct gel analysis, aliquots of each amplification reaction were electrophoretically separated in 2% agarose gels in Tris-acetic acid-EDTA containing 0.15 μg/ml of ethidium bromide. DNA was visualized by ultraviolet fluorescence. DNA molecular weight marker VIII (Boehringer Mannheim Biochemica, Mannheim, Germany) was included in each gel.

Slot-blot analysis was performed as previously described [19]. Briefly, 3 μl of the reaction mixture was denatured and the DNA was immediately applied to a nylon filter membrane (Hybond-N+; Amersham, les Ulis, France). The DNA samples were then hybridized with a homologous 32P-labeled 18-base oligonucleotide probe. Autoradiography was routinely performed for 2 h at -80°C using X-Omat autoradiograph film (Eastman Kodak, Rochester, N.Y., USA).

The sensitivity of the protocol used in this study, determined from experiments on human CMV-infected fibroblasts, has been previously reported [19]; it was concluded that the sensitivity of the protocol was one viral copy per 106 cells by slot-blot assay.

Results

Study population

Demographic characteristics and other markers of acute illness in the 23 mechanically ventilated patients are shown in Table 1. Anti-CMV IgG were detected in each patient’s serum. Thirteen patients had undergone a previous surgical procedure which was complicated by peritonitis (n=3), adult respiratory distress syndrome (ARDS) (n=2), pneumonia (n=2), mediastinitis (n=2), coma (n=1), myocardial infarction (n=1), and ischemic hepatitis (n=1), and 1 patient died the day after a surgical procedure for gastrointestinal bleeding. Ten patients had also been admitted to the ICU for a variety of disorders, including community-acquired pneumonia (n=3), pulmonary contusion (n=2), coma (n=2), ARDS (n=1), myocardial infarction with pulmonary edema (n=1), and pyleonephritis (n=1). Finally, 15 patients had a documented infection and 13 of these had sepsis syndrome at the time of the study. Among these 13 patients, 11 had septic shock. Overall mortality was 52%.

PBLs and BAL cells

In acute CMV infection

The amplified DNA extracted from PBLs and BAL cells of CMV-infected patients gave a positive signal for CMV when tested by gel electrophoresis and slot-blot analysis (Fig. 2, lanes A and C, columns 2, 3).
Table 1 Clinical and biochemical characteristics of patients (APACHE Acute Physiology and Chronic Health Evaluation, WBC white blood cell, AST aspartate aminotransaminase, PaO₂ partial pressure of oxygen in arterial blood, FiO₂ fractional inspired oxygen, ARDS adult respiratory distress syndrome)

|                          | Mean±SEM | Range |
|--------------------------|----------|-------|
| Number of patients       | 23       |       |
| Age (years)              | 61±3.4   | 26-83 |
| Sex, M/F                 | 14/9     |       |
| APACHE II score          | 25±2     | 8-50  |
| Previous surgical procedure\(^b\) (n) | 13       |       |
| Severity of underlying disease (n) | 9        |       |
| Fatal or ultimately fatal within 5 years | 14       |       |
| Non-fatal                | 14       |       |
| Patients with chronic alcohol abuse (n) | 4        |       |
| WBC count (10⁹/l)        | 15±2.1   | 1.3-37.7 |
| Lymphocyte count (10⁹/l) | 0.97±0.1 | 0.11-2.03 |
| Creatinine (µmol/l)      | 174±32   | 50-660 |
| Bilirubin (µmol/l)       | 56.5±18  | 5-333 |
| AST (mU/ml)              | 164±70   | 14-1130 |
| PaO₂/FiO₂ ratio          | 191±21   | 63-440 |
| Murray's ARDS score      | 1.7±0.3  | 0-3.8  |
| Duration of hospitalization (days) | 19±3    | 1-45   |
| No. who died             | 12       |       |

\(^a\) For quantitative variables
\(^b\) Includes 6 abdominal, 4 thoracic, 2 thoraco-abdominal, and 1 orthopedic

In asymptomatic seropositive patients

The amplification of the DNA extracted from BAL cells and PBLs of asymptomatic CMV-seropositive patients was negative for all patients when tested by direct gel electrophoresis analysis as well as by slot-blot assay (Fig. 2, lanes A and C, columns 6, 7).

In seropositive non-immunocompromised critically ill, mechanically ventilated patients

Amplification of the DNA extracted from BAL cells and PBLs of CMV-seropositive, critically ill, mechanically ventilated patients was negative for all patients when tested by direct gel electrophoresis as well as by slot-blot assay (Fig. 2, lanes A and C, columns 4, 5). In contrast, amplification of DNA from PBLs or BAL cells of the 268-bp fragment of the human β-globin gene gave positive results in all cases (Fig. 2, lane B, columns 4, 5).

Discussion

In the present study evaluating a series of 23 patients, the search for CMV in blood or BAL was negative by either PCR or viral cultures in all of the critically ill patients seropositive for CMV.

The population studied included critically ill patients with several factors which could contribute to depressed cellular immunity and therefore potentially affect the control of CMV latency. Lymphopenia (total lymphocyte count below 1.5 10⁹/l) was found in 87% of the 23 patients, this has been shown to be associated with stress, inflammation, infection and severity of disease [29]. Moreover, the majority of the patients had undergone a major surgical procedure, which has been shown to be associated with altered T-cell function [11, 29]. Last, some patients, especially those with septic shock, would have detectable levels of tumor necrosis factor [30], which was possibly associated with CMV reactivation [4].

The search for CMV DNA was performed by using PCR amplifying a 290-bp fragment from the first exon of the major CMV immediate early gene [20]. PCR has been reported to be successful in the detection of CMV in blood and BAL cells in CMV infection and has therefore been considered to be a particularly accurate diagnostic
method [12–18]. Of particular interest from the perspective of PCR is whether it is so sensitive that all infections, latent or active, will be detected. However, our assay did not detect CMV DNA in the blood of normal CMV seropositive healthy controls, as previously reported [19] – a result similar in other studies [12, 13, 16, 17]. Therefore, detection of CMV DNA by PCR could be related to an active CMV infection in the non-immunocompromised host. The choice of primers for amplification requires the use of highly conserved genomic sequences, such as those in the 240-kb CMV genome coding for the major immediate early antigen [27]. When testing DNA extracted from PBLs or BAL cells collected from CMV-infected patients, it was possible to detect the presence of CMV DNA in each of these patients. These patients were tested at random and could therefore be assumed to be infected by different wild strains of CMV. The choice of primers used for PCR in the present study generates the amplification of a sequence that can therefore be considered to be conserved in the various strains of CMV.

The sensitivity of the protocol used in this study has been previously reported [19] and is in accordance with that reported by other investigators [13, 15]. Therefore, the hypothesis explaining the negative findings in the present study is that the PCR assay is not sufficiently sensitive to detect very low levels of virus. However, the level of detection of the method used in the present study was shown to be one viral copy for 10⁴ cells, and PCR is now widely accepted to be a particularly sensitive method for viral detection [12–18].

CMV viremia has been demonstrated in patients with mediastinitis following cardiac surgery [3] and in septic patients with a high level of tumor necrosis factor [4], with a frequency of 20 and 96%, respectively. It has been shown that blood transfusion may be responsible for transmission of CMV DNA in 23 of 115 patients (20%) with mediastinitis following both reactivation and reinfection have been reported [31, 32]. Domart et al. reported the presence of CMV viremia in 23 of 115 patients (20%) with mediastinitis following cardiac surgery [3]. Only 8 of the 22 patients tested were seropositive for CMV before surgery and the viral shedding appeared to be related to perioperative blood transfusions [33]. Since CMV transmission by blood transfusion can be prevented by using leukocyte-poor blood components [34], we systematically performed blood filtration for the patients in this study. Another study provided substantial results concerning the reactivation of CMV in septic patients with high levels of plasma tumor necrosis factor [4]. In most of the septic patients CMV was demonstrated in blood by either PCR or viral culture after centrifugation, but no signs or symptoms of CMV disease were found in these patients despite their active CMV infection. However, in this study no information on blood transfusion was reported, and some of these patients might have suffered exogenous transmission of CMV. Moreover, the severity of illness, the severity of underlying medical conditions, and the treatment given may have been different from that in our patient population.

We have also failed to demonstrate a potential reactivation of CMV in the lung. The lung has been shown to be a potential site of CMV latency [8], though the precise sites of latent CMV are not known. Alveolar macrophages do not harbor latent CMV in the lungs of asymptomatic CMV-seropositive patients; pneumocytes and/or endothelial cells can therefore be considered to be potential candidates for CMV latency [19]. Acute lung injury could interfere with the host's immune system and therefore lead to CMV reactivation. This could be of particular interest since it is known that CMV induces immunosuppression [9], which could promote pulmonary infection. However, in our study, whatever the lung disease, no CMV reactivation could be demonstrated in the lung.

In conclusion, despite the use of a very sensitive method – PCR amplification – and two methods of viral cultures, we were unable to demonstrate reactivation of CMV either in blood or lung in critically ill mechanically ventilated non-immunocompromised patients. These results suggest that, in the absence of exogenous transmission, CMV reactivation is uncommon in such patients.

References

1. Smith CB (1989) Cytomegalovirus pneumonia: state of the art. Chest 95:182–187
2. Alford CA, Brit WJ (1990) Cytomegalovirus. In: Fields BN, Knipe DM, Chesnok RM, Hirsch MS, Melnick JL, Monath TR, Roizman B (eds) Virology, 2nd edn. Raven Press, New York, pp 1981–2010
3. Domart Y, Trouillet J-L, Fagon JY, Chastre J, Brun-Vezinet F, Gibert C (1990) Incidence and morbidity of cytomegaloviral infection in patients with mediastinitis following cardiac surgery. Chest 97:18–22
4. Döcke WD, Prösch S, Fietze E, Kimel V, Zuckermann H, Klug C, Syrbe U, Krüger DH, Von Baehr R, Volkt HD (1994) Cytomegalovirus reactivation and tumor necrosis factor. Lancet 343:268–269
5. Schrier RD, Nelson JA, Oldstone MBA (1985) Detection of human cytomegalovirus in peripheral blood lymphocytes in a natural infection. Science 230:1048–1051
6. Taylor-Wiederman J, Sissons JGP, Borysiwicz LK, Sinclair JH (1991) Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J Gen Virol 72: 2059–2064
7. Adler SP (1983) Transfusion-associated cytomegalovirus infections. Rev Infect Dis 5:977–993
8. Tookeby CB, Carrigan DR (1989) Immunohistochemical detection of an immediate early antigen of human cytomegalovirus in normal tissues. J Infect Dis 160: 741–750
9. Griffiths PD, Grundy JE (1987) Molecular biology and immunology of cytomegalovirus. Biochem J 241:313–324

10. Michelson S, Plotkin SA (eds) (1993) Multidisciplinary approach to understanding cytomegalovirus disease. In: Proceedings of the fourth international cytomegalovirus workshop: multidisciplinary approaches to understanding CMV disease. Elsevier, Amsterdam

11. Abraham E (1989) Cellular and humoral immunity in the critically ill patient. In: Shoemaker WC, Ayres S, Grevik A, Holbrook PR, Thompson WL (eds) Textbook of critical care, 2nd edn. Saunders, Philadelphia, pp 1024–1028

12. Shibata D, Martin WJ, Applemann MD, Causey DM, Leedom JM, Arnhem N (1988) Detection of cytomegalovirus DNA in peripheral blood of patients infected with human immunodeficiency virus. J Infect Dis 158:1185–1192

13. Cassol SA, Poon MC, Pal R, Naylor MJ, Culver-James J, Bowen TJ, Russel JA, Krawetz SA, Pon RT, Hoar DI (1989) Primer-mediated enzymatic amplification of cytomegalovirus (CMV) DNA. Application to the early diagnosis of CMV infection in marrow transplant recipients. J Clin Invest 83:1109–1115

14. Einsele H, Steidle M, Zweygbergter A, Ricci S, Geslin R, Goossens M, Bertrand J-F, Linde A (1993) Diagnosis of cytomegalovirus infection in bronchoalveolar lavage by polymerase chain reaction, in comparison with virus isolation and detection of viral antigen. Scand J Infect Dis 25:421–427

15. Wilhelm S, Plotkin SA (eds) (1993) Diagnosis of cytomegalovirus disease. In: Proceeding the fourth international cytomegalovirus workshop: multidisciplinary approaches to understanding CMV disease. Elsevier, Amsterdam

16. Xu W, Sundqvist V-A, Bryttning M, Linde A (1993) Diagnosis of cytomegalovirus infections using polymerase chain reaction, virus isolation and serology. Scand J Infect Dis 25:311–316

17. Buffone GI, Frost A, Samo T, Demmler GJ, Cagle PT, Lawrence EC (1993) The diagnosis of CMV pneumonitis in lung and heart/lung transplant patients by PCR compared with traditional laboratory criteria. Transplantation 56:342–347

18. Eriksson B-M, Bryttning M, Zweygber-Wingart B, Hillerdal G, Olding-Stenkvist E, Linde A (1993) Diagnosis of cytomegalovirus in bronchoalveolar lavage by polymerase chain reaction, in comparison with virus isolation and detection of viral antigen. Scand J Infect Dis 25:421–427

19. Fajac A, Vidaud M, Lebargy F, Stephan E, Ricci S, Geslin P, Goossens M, Bertrand J-F, Linde A (1994) Evaluation of human cytomegalovirus latency in alveolar macrophages. Am J Respir Crit Care Med 149:495–499

20. Hennighausen L, Fleckenstein B (1986) Nuclear factor I interacts with five DNA elements in the promoter region of the human cytomegalovirus major immediate early gene. EMBO J 5:1367–1371

21. Paia CV, Wold AD, Smith TF (1987) Detection of cytomegalovirus infections in specimens other than urine by shell vial assay and conventional culture cell cultures. J Clin Microbiol 25:755–757

22. McCabe WR, Jackson GG (1962) Gram-negative bacteria I. Etiology and ecology. Arch Intern Med 110:847–864

23. Knaus WA, Draper EA, Wagner DP, Zimmerman JE (1985) APACHE II: a severity of disease classification system. Crit Care Med 13:818–829

24. Murray JF, Matthay A, Luce JM, Flick MR (1988) An expanded definition of the adult respiratory distress syndrome. Am J Respir Crit Care Med 138:720–723

25. Bone RC, Fisher CI, Cremmer TP, Stimson GJ, Metz CA, Balk RA (1989) Sepsis syndrome: a valid clinical entity. Crit Care Med 17:389–393

26. Higuchi R (1989) Simple and rapid preparation of samples for PCR. In: Erlich HA (ed) PCR technology: principles and applications for DNA amplification. Stockton Press, New York, pp 31–38

27. Pritchett RF (1980) DNA nucleotide sequence heterogeneity between the Towne and AD 169 strains of cytomegalovirus. J Virol 36:162–171

28. Saiki RK, Sharp F, Faloona F, Mullis KB, Horn GT, Erlich HA, Arnhem N (1985) Enzymatic amplification of β-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 230:1350–1354

29. Sun X, Iles M, Weissman C (1993) Physiologic variables and fluid resuscitation in the postoperative intensive care unit patient. Crit Care Med 21:555–561

30. Casey LC, Balk RA, Bone RC (1993) Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 119:771–778

31. Adler SP, Baggett J, McVoy M (1985). Transfusion-associated cytomegalovirus infections in seropositive cardiac surgery patients. Lancet II:743–746

32. Grundy JE, Super M, Sweny P, Moorhead J, Lui SF, Berry NJ, Fernando ON, Griffiths PD (1988) Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus. Lancet II:132–135

33. Van der Salm T (1990) Cytomegalovirus: more dangerous to the cardiac surgical patient than we thought? Chest 97:3–4

34. Gilbert GL, Hudson IL, Hayes K, James J, and the neonatal cytomegalovirus infection study group (1989) Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leukocytes. Lancet I:2228–1231